药物开发中下一代测序 (NGS) 的全球市场

全球药物开发下一代测序（NGS）市场预计将从2023年的13亿美元增长到2028年的29亿美元，年复合成长率为17.7%。

按地区划分，北美市场预计将从2023年的5.398亿美元增长到2028年的12亿美元，复合年复合成长率为18.0%。此外，亚太市场预计将从2023年的3.11亿美元增长到2028年的7.436亿美元，年复合成长率为19.0%。

本报告调查了全球下一代测序（NGS）药物开发市场，提供了市场和技术概述、市场影响因素和市场机会分析、市场规模趋势和预测，以及按不同细分市场和地区进行的细分。详细分析、ESG发展、技术/专利动向、竞争形势、主要企业概况等。

目录

第1章简介

第2章总结/要点

第3章市场概况

• 科技背景
• DNA 的结构和重要性
• DNA测序技术
• 全基因组测序
• 靶向重测序
• 芯片测序
• RNA测序
• 甲基化测序
• DNA测序的历史
• 桑格测序
• 下一代测序 (NGS) 概述
• NGS的优点
• Roche 454 Pyrosequencing
• Illumina NGS
• Thermo Fisher Scientific (Life Technologies) NGS
• 测序设备
• 台式测序仪
• 信息技术
• NGS在药物开发中的应用
• NGS服务提供商

第4章市场动态

• 市场促进因素
• 利用 NGS 技术扩大研发活动
• 医疗费用增加
• 测序平台的技术进步
• 向精准医疗过渡
• 对 NGS 为癌症患者设计个人化医疗的需求不断增长
• 高精度/低成本
• 市场抑制因素
• 与 NGS 技术相关的限制
• 临床测序技术的其他课题
• 市场机会
• NGS 研发的不断增长为製造商创造了有利的机会

第5章药物开发中的 NGS 市场（按产品类型）

• 设备
• 消耗品
• 服务

第6章药物开发中的 NGS 市场：按最终用户分类

• 製药和生物技术公司
• 学术研究中心
• 其他的

第7章药物开发中的 NGS 市场：按地区

• 市场概览/讨论
• 北美
• 亚太地区
• 欧洲
• 其他地区

第8章药物开发的可持续性 NGS：ESG 视角

• ESG：概述
• 药物开发的可持续性 NGS：ESG 视角
• ESG 关键课题
• 消费者对 ESG 的态度
• 行业ESG绩效分析
• 案例分析
• 环境
• 社会
• 治理
• BCC的结语

第9章新技术和发展

• 概述
• 市场上的新兴技术
• 人工智能在NGS中的应用
• 单分子实时测序
• 纳米孔技术
• 基于显微镜的测序

第10章专利分析

第11章併购与资金筹措预测

第12章竞争形势

• 世界公司排名
• 世界公司排名：设备
• 世界公司排名：消耗品
• 世界公司排名：服务

第13章公司简介

• 10X GENOMICS
• AGILENT TECHNOLOGIES INC.
• BGI (BEIJING GENOMICS INSTITUTE)
• BIO-RAD LABORATORIES INC.
• CD GENOMICS
• ILLUMINA INC.
• INTEGRATED DNA TECHNOLOGIES INC.
• MICRONOMA
• NEW ENGLAND BIOLABS
• OXFORD NANOPORE TECHNOLOGIES
• PACIFIC BIOSCIENCES OF CALIFORNIA INC.
• PERKINELMER INC.
• PROMEGA CORP.
• PSOMAGEN INC.
• 医学精准（原 APOCELL）
• QIAGEN
• ROCHE HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• TAKARA BIO INC.
• TECAN GROUP LTD.

第14章附录：首字母缩写词

Highlights:

The global next-generation sequencing (NGS) market in drug development should reach $2.9 billion by 2028 from $1.3 billion in 2023 at a compound annual growth rate (CAGR) of 17.7% for the forecast period of 2023 to 2028.

North American NGS market in drug development is expected to grow from $539.8 million in 2023 to $1.2 billion in 2028 at a CAGR of 18.0% for the forecast period of 2023 to 2028.

Asia-Pacific NGS market in drug development is expected to grow from $311 million in 2023 to $743.6 million in 2028 at a CAGR of 19.0% for the forecast period of 2023 to 2028.

Report Scope:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

BCC Research summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes:

• 52 data tables and 39 additional tables
• An overview of the global markets for next-generation sequencing on drug development
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region
• Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Research Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Introduction
• Technology Background
• Structure and Importance of DNA
• DNA Sequencing Technologies
• Whole Genome Sequencing
• Targeted Resequencing
• ChIP Sequencing
• RNA Sequencing
• Methylation Sequencing
• History of DNA Sequencing
• Sanger Sequencing
• Introduction to Next Generation Sequencing (NGS)
• Advantages of NGS
• Roche 454 Pyrosequencing
• Illumina NGS
• Thermo Fisher Scientific (Life Technologies) NGS
• Sequencing Instruments
• Benchtop Sequencers
• Informatics Technologies
• NGS in Drug Development
• NGS Service Providers

Chapter 4 Market Dynamics

• Market Drivers
• Increasing R&D Activities using NGS technologies
• Increase in Healthcare Expenditure
• Technological Advancements in Sequencing Platforms
• Shift Towards Precision Medicine
• Growing demand of NGS for Designing Individualized Medicine to Cancer Patients
• High Accuracy and Low Cost
• Market Restraints
• Limitations Associated with NGS Technology
• Other Clinical Sequencing Technology Challenges
• Market Opportunities
• Rising R&D in NGS creates lucrative Opportunities for Manufacturers

Chapter 5 NGS in Drug Development by Product Type

• Introduction
• Instruments
• Consumables
• Services

Chapter 6 NGS Market in Drug Development by End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Centers
• Other End Users

Chapter 7 NGS Market in Drug Development by Region

• Market Overview and Discussion
• North America
• Asia-Pacific
• Europe
• Rest of the World

Chapter 8 Sustainability of NGS in Drug Development: An ESG Perspective

• Introduction to ESG
• Sustainability of NGS in Drug Development: An ESG Perspective
• Key ESG Issues
• Consumer Attitudes Towards ESG
• Industry ESG Performance Analysis
• Case Study
• Environment
• Social
• Governance
• Concluding Remarks from BCC

Chapter 9 Emerging Technologies and Developments

• Overview
• Emerging Technologies in the Market
• Application of Artificial Intelligence (AI) in NGS
• Single-Molecule Real-Time Sequencing
• Nanopore Technology
• Microscopy-Based Sequencing

Chapter 10 Patent Analysis

• Introduction
• Patents on NGS by Region

Chapter 11 M&A and Funding Outlook

• M&A Analysis

Chapter 12 Competitive Landscape

• Global Company Ranking
• Global Company Ranking for NGS Instruments in Drug Development
• Global Company Ranking for NGS Consumables in Drug Development
• Global Company Ranking for NGS Services in Drug Development

Chapter 13 Company Profiles

• 10X GENOMICS
• AGILENT TECHNOLOGIES INC.
• BGI (BEIJING GENOMICS INSTITUTE)
• BIO-RAD LABORATORIES INC.
• CD GENOMICS
• ILLUMINA INC.
• INTEGRATED DNA TECHNOLOGIES INC.
• MICRONOMA
• NEW ENGLAND BIOLABS
• OXFORD NANOPORE TECHNOLOGIES
• PACIFIC BIOSCIENCES OF CALIFORNIA INC.
• PERKINELMER INC.
• PROMEGA CORP.
• PSOMAGEN INC.
• PRECISION FOR MEDICINE, FORMERLY APOCELL
• QIAGEN
• ROCHE HOLDING AG
• THERMO FISHER SCIENTIFIC INC.
• TAKARA BIO INC.
• TECAN GROUP LTD.

Chapter 14 Appendix: Acronyms

List of Tables

• Summary Table : Global Market for NGS in Drug Development, by Region, Through 2028
• Table 1 : DNA Translation and Transcription
• Table 2 : Long-range DNA Structure
• Table 3 : DNA Sequencing Workflow
• Table 4 : DNA Sequencing Historical Timeline, 1955-2017
• Table 5 : Sequencing Technology Development, 1990-2020+
• Table 6 : Cost to Sequence a Single Human Genome, 2001-2018
• Table 7 : Sanger Sequencing Summary
• Table 8 : Sanger Sequencing Improvements
• Table 9 : NGS Technologies
• Table 10 : Roche NGS Workflow
• Table 11 : Illumina NGS Workflow
• Table 12 : Thermo Fisher NGS Workflow
• Table 13 : NGS Instruments
• Table 14 : Benchtop and Handheld Sequencer Platforms
• Table 15 : Characteristics of NGS Platforms
• Table 16 : NGS Bioinformatics Workflow
• Table 17 : Sequence Annotation Steps
• Table 18 : NGS Service Providers
• Table 19 : NGS Cost per Sample
• Table 20 : Future Challenges for Implementing NGS
• Table 21 : Global Market for NGS in Drug Development, by Product Type, Through 2028
• Table 22 : Global Market for NGS Instruments in Drug Development, by Region, Through 2028
• Table 23 : Global Market for NGS Consumables in Drug Development, by Region, Through 2028
• Table 24 : Global Market for NGS Services in Drug Development, by Region, Through 2028
• Table 25 : Global Market for NGS in Drug Development, by End User, Through 2028
• Table 26 : Global Market for NGS in Drug Development, by Region, Through 2028
• Table 27 : North American Market for NGS in Drug Development, by Country, Through 2028
• Table 28 : Asia-Pacific Market for NGS in Drug Development, by Country, Through 2028
• Table 29 : European Market for NGS in Drug Development, by Country, Through 2028
• Table 30 : RoW Market for NGS in Drug Development, Through 2028
• Table 31 : Key Focus Areas in ESG Metrics
• Table 32 : Net-Zero GHG Commitments, Major NGS Companies
• Table 33 : ESG Rankings for Major NGS Companies, 2023*
• Table 34 : CDP Scope Card for Major NGS Companies, 2022
• Table 35 : U.S. Patent Related to NGS
• Table 36 : Worldwide Patent Related to NGS
• Table 37 : European Patents Related to NGS
• Table 38 : Chinese Patents Related to NGS
• Table 39 : Japanese Patents Related to NGS
• Table 40 : Global Market Rankings, NGS in Drug Development, by Manufacturer, 2022
• Table 41 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
• Table 42 : Global Market Rankings for NGS Instruments in Drug Development, by Manufacturer, 2022
• Table 43 : Global Market Rankings for NGS Services in Drug Development, by Manufacturer, 2022
• Table 44 : 10x Genomics: Net Annual Revenue, by Segment, 2020-2022
• Table 45 : 10x Genomics: Net Annual Revenue, by Region/Country, 2020-2022
• Table 46 : 10x Genomics: Products and Services
• Table 47 : Agilent Technologies Inc.: Net Revenue, by Segment, 2020-2022
• Table 48 : Agilent Technologies Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 49 : Agilent Technologies Inc.: Net Revenue, by End Market, 2020-2022
• Table 50 : Agilent Technologies Inc.: Revenue, by Type, 2020-2022
• Table 51 : Agilent Technologies Inc.: Net Revenue, by Region, 2020-2022
• Table 52 : Agilent Technologies Inc.: NGS Products
• Table 53 : BGI: Products and Services
• Table 54 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 55 : Bio-Rad Laboratories Inc.: Company Financials, 2020-2022
• Table 56 : Bio-Rad Laboratories Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 57 : Bio-Rad Laboratories Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 58 : Illumina Inc.: Net Revenue, 2020-2022
• Table 59 : Illumina Inc.: Revenue, by Source, 2021 and 2022
• Table 60 : Illumina Inc.: Net Revenue, by Region, 2020-2022
• Table 61 : Illumina Inc.: Drug Discovery and Development Products
• Table 62 : Oxford Nanopore Technologies: Products and Services
• Table 63 : Oxford Nanopore Technologies: Net Revenue, by Segment, 2020-2022
• Table 64 : Oxford Nanopore Technologies: LSRT Revenue, by Region/Country, 2020-2022
• Table 65 : Pacific Biosciences of California Inc.: Net Revenue, by Segment, 2020-2022
• Table 66 : Pacific Biosciences of California Inc.: Net Revenue, by Region, 2020-2022
• Table 67 : PacBio: Products and Services
• Table 68 : PerkinElmer Inc.: Net Revenue, by Operating Segment, 2020-2022
• Table 69 : PerkinElmer Inc.: Net Revenue, by Business Segment, 2020-2022
• Table 70 : PerkinElmer Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 71 : Qiagen: Financial Revenue, 2020-2022
• Table 72 : Qiagen: Net Revenue, by Customer Class, 2020-2022
• Table 73 : Qiagen: Net Revenue, by Product Group, 2020-2022
• Table 74 : Qiagen: Net Revenue, by Region/Country, 2020-2022
• Table 75 : Qiagen: NGS Products and Services
• Table 76 : Roche Holding AG: Net Revenue, by Business Segment, 2020-2022
• Table 77 : Roche Holding AG: Diagnostics Revenue, by Segment, 2020-2022
• Table 78 : Roche Holding AG: Pharmaceuticals Revenue, by Segment, 2021 and 2022
• Table 79 : Roche Holding AG: Net Revenue, by Region/Country, 2021 and 2022
• Table 80 : Roche Holding AG: NGS Products and Services
• Table 81 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
• Table 82 : Thermo Fisher Scientific Inc.: Net Revenue, by Segment, 2020-2022
• Table 83 : Thermo Fisher Scientific Inc.: Net Revenue, by Region, 2020-2022
• Table 84 : Thermo Fisher Scientific Inc.: Products and Services
• Table 85 : Takara Bio Inc.: Net Revenue, by Segment, 2021 and 2022
• Table 86 : Takara Bio Inc.: Net Revenue, by Region/Country, 2020-2022
• Table 87 : Tecan Group Ltd.: Company Financials, 2020 and 2022
• Table 88 : Tecan Group Ltd.: Net Revenue, by Business Segment, 2020-2022
• Table 89 : Tecan Group Ltd.: Net Revenue, by Region, 2022
• Table 90 : Acronyms Used in This Report

List of Figures

• Summary Figure A : Global Market for NGS in Drug Development, by Region, 2020-2028
• Summary Figure B : Global Market Shares of NGS in Drug Development, by Region, 2022
• Figure 1 : Whole Genome Sequencing
• Figure 2 : Number of NGS Tests, Research Activities, Different Global Centers, 2023
• Figure 3 : The Road from NGS to Personalized Medicine
• Figure 4 : Global Market for NGS in Drug Development, by Product Type, 2020-2028
• Figure 5 : Global Market Shares of NGS in Drug Development, by Product Type, 2022
• Figure 6 : Global Market for NGS Instruments in Drug Development, by Region, 2020-2028
• Figure 7 : Global Market Shares of NGS Instruments in Drug Development, by Region, 2022
• Figure 8 : Global Market for NGS Consumables in Drug Development, by Region, 2020-2028
• Figure 9 : Global Market Shares of NGS Consumables in Drug Development, by Region, 2022
• Figure 10 : Global Market for NGS Services in Drug Development, by Region, 2020-2028
• Figure 11 : Global Market Shares of NGS Services in Drug Development, by Region, 2022
• Figure 12 : Global Market for NGS in Drug Development, by End User, 2020-2028
• Figure 13 : Global Market Shares of NGS in Drug Development, by End User, 2022
• Figure 14 : Global Market for NGS in Drug Development, by Region, 2020-2028
• Figure 15 : Global Market Shares of NGS in Drug Development, by Region, 2022
• Figure 16 : North American Market for NGS in Drug Development, by Country, 2020-2028
• Figure 17 : North American Market Shares of NGS in Drug Development, by Country, 2022
• Figure 18 : Asia-Pacific Market for NGS in Drug Development, by Country, 2020-2028
• Figure 19 : Asia-Pacific Market Shares of NGS in Drug Development, by Country, 2022
• Figure 20 : European Market for NGS in Drug Development, by Country, 2020-2028
• Figure 21 : European Market Shares of NGS in Drug Development, by Country, 2022
• Figure 22 : How a Strong ESG Proposition Benefits Businesses
• Figure 23 : Research Communities, Key Sustainable Practices, Research Laboratories
• Figure 24 : Illumina Inc.'s Most Material ESG Issues
• Figure 25 : Emerging Technologies in the NGS Market in Drug Development
• Figure 26 : 10x Genomics: Net Revenue, 2020-2022
• Figure 27 : 10x Genomics: Revenue Share, by Segment, 2022
• Figure 28 : 10x Genomics: Revenue Share, by Region/Country, 2022
• Figure 29 : Agilent Technologies Inc.: Revenue Share, by Segment, 2022
• Figure 30 : Agilent Technologies Inc.: Revenue Share, by Business Segment, 2022
• Figure 31 : Agilent Technologies Inc.: Revenue Share, by End Market, 2022
• Figure 32 : Agilent Technologies Inc.: Revenue Share, by Type, 2022
• Figure 33 : Agilent Technologies Inc.: Revenue Share, by Region, 2022
• Figure 34 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Segment, 2022
• Figure 35 : Bio-Rad Laboratories Inc.: Revenue Share, by Region/Country, 2022
• Figure 36 : Illumina Inc.: Revenue Share, by Segment, 2022
• Figure 37 : Illumina Inc.: Revenue Share, by Segment, 2022
• Figure 38 : Oxford Nanopore Technologies: Net Revenue, 2020-2022
• Figure 39 : Oxford Nanopore Technologies: Revenue Share, by Region/Country, 2022
• Figure 40 : Pacific Biosciences of California Inc.: Revenue Share, by Segment, 2022
• Figure 41 : Pacific Biosciences of California Inc.: Revenue Share, by Region, 2022
• Figure 42 : PerkinElmer Inc.: Revenue Share, by Operating Segment, 2022
• Figure 43 : PerkinElmer Inc.: Revenue Share, by Business Segment, 2022
• Figure 44 : PerkinElmer Inc.: Revenue Share, by Region/Country, 2022
• Figure 45 : Qiagen: Revenue Share, by Segment, 2022
• Figure 46 : Qiagen: Revenue Share, by Customer Class, 2022
• Figure 47 : Qiagen: Revenue Share, by Product Group, 2022
• Figure 48 : Qiagen: Revenue Share, by Region/Country, 2022
• Figure 49 : Roche Holding AG: Revenue Share, by Business Segment, 2022
• Figure 50 : Roche Holding AG: Diagnostics Revenue Share, by Segment, 2022
• Figure 51 : Roche Holding AG: Pharmaceuticals Revenue Share, by Segment, 2022
• Figure 52 : Roche Holding AG: Revenue Share, by Region/Country, 2022
• Figure 53 : Thermo Fisher Scientific Inc.: Net Revenue, 2020-2022
• Figure 54 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
• Figure 55 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2022
• Figure 56 : Thermo Fisher Scientific Inc.: Revenue Share, by Region, 2022
• Figure 57 : Takara Bio Inc.: Net Revenue, 2020-2022
• Figure 58 : Takara Bio Inc.: Revenue Share, by Segment, 2022
• Figure 59 : Takara Bio Inc.: Revenue Share, by Region/Country, 2022
• Figure 60 : Tecan Group Ltd.: Revenue Share, by Business Segment, 2022
• Figure 61 : Tecan Group Ltd.: Revenue Share, by Region, 2022